Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study

The global, randomized NAPOLI‐1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (nal‐IRI+5‐FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine‐based therapy. Median overall survival (OS) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Yung‐Jue, Li, Chung‐Pin, Lee, Kyung‐Hun, Chiu, Chang‐Fang, Park, Joon Oh, Shan, Yan‐Shen, Kim, Jun Suk, Chen, Jen‐Shi, Shim, Hyun‐Jeong, Rau, Kun‐Ming, Choi, Hye Jin, Oh, Do‐Youn, Belanger, Bruce, Chen, Li‐Tzong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004519/
https://www.ncbi.nlm.nih.gov/pubmed/31789476
http://dx.doi.org/10.1111/cas.14264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004519/
https://www.ncbi.nlm.nih.gov/pubmed/31789476
http://dx.doi.org/10.1111/cas.14264

Ejemplares similares